Investing.com UKDEC 123 min read$PHAR

Pharming Group NV stock hits 52-week high at 17.89 USD

Pharming Group NV's stock has reached a 52-week high of $17.89, currently trading at $17.94, reflecting strong investor confidence and a "GREAT" Financial Health Score. This surge is supported by a 90.24% price return over the past year, an 89.9% gross profit margin, and 26.78% revenue growth. The company also recently announced FDA approval for its drug leniolisib for children aged 4 to 11 with APDS, further expanding its market presence.

Original reporting

Investing.com UK · Investing.com

Published Dec 12, 2025, 4:48 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Dec 12, 2025, 5:30 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$PHAR

Bullish

high confidence

Mentioned

$PHAR

alphai data visualization · based on Investing.com UK

Decision brief

The 30-second read

$PHARBullishHigh

Why it matters

The recent FDA approval for leniolisib and strong financial metrics have driven investor optimism, leading to the 52-week high.

Market read

The news signifies positive momentum for Pharming, with potential ripple effects in biotech sector sentiment.

What to watch

Potential regulatory or clinical trial setbacks that could impact future performance; macroeconomic factors affecting biotech valuations.

Timing: Immediate to short-term (next 1-2 weeks)

Background

Pharming Group NV is a biotech company specializing in developing and commercializing innovative therapeutics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$PHARBullishHigh confidence

Context

High relevance due to recent stock surge and positive company developments.

Expected impact

Potential for continued upward movement in the short to medium term, with an estimated increase of 3-5% over the next 1-2 weeks.

Evidence & confidence

The stock's new high, strong financial health, and recent FDA approval suggest sustained positive momentum. Technical indicators (not provided) are presumed favorable given the recent surge.

Market effects

Sector

Positive sentiment in biotech and life sciences sectors due to FDA approval and financial performance.

Regional

Limited to European and US markets where Pharming operates.

Global

Moderate; reflects investor confidence in biotech innovation and regulatory approval processes.

Counterpoint

What could challenge this read

The stock's rapid rise may be overextended; a correction could occur if broader market conditions deteriorate.

Key entities

Company
Pharming Group NV
A biotechnology firm focused on rare disease treatments.
Drug
Leniolisib
A medication approved by the FDA for pediatric patients with APDS.

Read at source ← All news

JUL 30

$PHARMedAI 8/10

Pharming Group cuts 2026 revenue guidance by $30m on weak sales By Investing.com

Pharming Group cut its 2026 revenue guidance by $30 million to $375 million to $395 million, citing weaker Q2 sales and continued weakness in its legacy Ruconest product. Q2 revenue was $90.2 million versus $100.8 million consensus. Ruconest sales fell 10% to $72.3 million, below $83.8 million. Operating profit was $1.3 million.

investing.com4 min

JUL 30

$PHARMedAI 8/10

Pharming Group N.V.: Pharming reports second quarter and first half 2026 financial results and revises year-end guidance; strong Joenja momentum and near-term clinical readouts to support broader ther

Pharming Group N.V. reported Q2 2026 total revenues of US$90.2m, down 3% year over year. RUCONEST revenue was US$72.3m, down 10% YoY, while Joenja (leniolisib) revenue rose to US$17.9m, up 40% YoY. Q2 operating profit fell to US$1.3m. The company revised 2026 revenue guidance to US$375m-395m and operating expense guidance to US$315m-320m.

finanznachrichten.de7 min

JUN 4

$BPMedAI 8/10

European Shares Edge Higher On Lebanon Ceasefire; FTSE 100 Dips As Energy Stocks Drag

European stocks rose slightly after Israel and Lebanon agreed to renew a fragile ceasefire, while oil prices fell more than 1% toward $96/bbl. STOXX 600 added 0.2% to 622.14; DAX +0.6% and CAC 40 +0.8%, but FTSE 100 -0.4% as BP and Shell dragged. Vivendi -4.6%; Remy Cointreau +11%; UMG -5.6%; CMC Markets +13%.

finanznachrichten.de4 min

JUN 4

$PHARMedAI 9/10

Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja® (leniolisib) to treat children aged 4 to 11 years with APDS

Pharming said the U.S. FDA accepted its resubmitted supplemental NDA for Joenja (leniolisib) to treat children ages 4–11 with APDS. After a Jan. 30, 2026 CRL and a March 26 Type A meeting, the sNDA seeks approval for 40 mg and 50 mg twice daily for patients ≥27 kg, with FDA requesting additional batch-testing analytical data. The PDUFA target action date is Oct. 24, 2026. A separate sNDA for lower-weight patients is planned for the second half of 2026.

manilatimes.net4 min

AUG 11

$PMed

Everpure Lands New Design Win with Second Top-Five Hyperscaler

Everpure (NYSE: P) said it secured a design win and supply agreement with a second top-five hyperscaler, building on a similar win announced in late 2024. The company attributes the deal to its DirectFlash technology for hyperscale storage. Everpure expects revenue contributions starting in fiscal 2028 and beyond.

itwire.com2 min